



Frequently Asked Questions

1. What has Valeritas announced?

Valeritas announced that it has reached an agreement to sell substantially all of the business to Zealand Pharma A/S, a Denmark-based biotechnology company. Upon closing, Zealand will also assume certain of the Company's liabilities related to the ongoing business.

To accomplish the sale in the most efficient manner, Valeritas and its subsidiaries filed voluntary Chapter 11 petitions in the United States Bankruptcy Court for the District of Delaware.

Subject to Bankruptcy Court approval, Zealand will serve as the "stalking horse" bidder, and other prospective buyers will have the opportunity to bid on the business. Zealand will be able to counter any qualified competing bids and top any final bid.

2. Why did Valeritas agree to sell the business to Zealand?

After thoughtful consideration of various strategic alternatives, Valeritas determined that a process to sell the business is the best path to maximize value for all stakeholders.

It is advantageous to enter the Chapter 11 process with an agreed offer from Zealand, which intends, at close, to retain nearly all of Valeritas' employees. Zealand intends to build a successful commercial competitor in the U.S. diabetes market and has late stage programs in areas related to Valeritas therapies.

3. Why has Valeritas filed for Chapter 11?

Valeritas filed for Chapter 11 to accomplish the sale in the most efficient manner.

4. Does Valeritas have enough money to continue operating while in Chapter 11?

Valeritas has obtained a commitment for debtor-in-possession ("DIP") financing from HB Fund LLC. Subject to Court approval, this DIP financing will provide funds to support ongoing operations during the process.

5. Will the Company continue to supply and distribute V-Go® during the Chapter 11 process?

Yes, the Company will continue to produce and sell V-Go® throughout the process.

6. I'm an employee. Will I be paid my wages/salary and receive my benefits as usual during the Chapter 11 process?

We anticipate that there will be no changes with respect to when and how you receive your paychecks as a result of the filing. We expect to continue meeting payroll obligations on our normal payroll cycle for all employees for so long as you are employed by Valeritas.

We have filed with the Bankruptcy Court a “wage and benefits” motion seeking authority to meet our payroll obligations and provide medical and dental benefits in the normal course, and it is customary for that request to be considered promptly. This type of motion is routinely granted.

7. I’m a patient who uses V-Go®. Am I still entitled to receive co-pay assistance and support, such as training and reimbursement?

These types of customer programs are a key aspect of our business and we intend to continue them in the normal course.

8. Will the Company continue to offer patient and healthcare provider services under the V-Go® Cares Umbrella?

Yes, the Company will continue to offer all the patient and healthcare provider services under its V-Go® Cares Umbrella, and its salesforce will continue to promote the benefits of V-Go® as well as educate and train healthcare providers and patients on V-Go® usage.

9. I’m a vendor. Will I be paid for authorized goods delivered/services rendered to Valeritas after the filing date?

Valeritas will pay vendors in the ordinary course of business for all authorized goods delivered and services rendered *after* the filing date.

Payments for these “postpetition” obligations are generally given priority payment status in a Chapter 11 proceeding, providing additional protection to vendors moving forward.

Valeritas has obtained a commitment for debtor-in-possession (“DIP”) financing from HB Fund LLC. Subject to Court approval, this DIP financing will provide sufficient liquidity to support ongoing operations during the process.

10. What happens next from a legal process standpoint?

The Company has filed with the Bankruptcy Court a series of customary motions seeking to continue operating its business as usual and uphold its commitments to its valued employees and other stakeholders during the process. Approval of these “first day” motions, which the Company expects to receive in short order following a hearing, will help facilitate a smooth transition into Chapter 11.

The Company also filed a motion seeking to designate Zealand as the “stalking horse” bidder and to receive approval of bidding procedures that will provide other prospective buyers with the opportunity to bid on the business, with the goal of maximizing value. Among other things, the bidding procedures will establish a timeline for submission of bids, an auction (if required), and a hearing to approve the sale.

11. Where can I go for more information and updates?

Information about Valeritas' Chapter 11 proceeding, including access to Bankruptcy Court documents, is available on this website (www.kccllc.net/valeritas).

For vendors, we have set up a dedicated hotline at (877) 709-4747 (toll-free). You may also submit an inquiry via email to ValeritasInfo@kccllc.com.

Patients should continue to call the V-Go[®] Customer Care line at (866) 881-1209 for support with V-Go[®].

Employees should continue to reach out to their managers with any questions.